Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A human study of a novel bladder MRI contrast agent LP-20 for detecting bladder tumor progression to muscle-invasive bladder cancer

Next Previous
Trial Profile

A human study of a novel bladder MRI contrast agent LP-20 for detecting bladder tumor progression to muscle-invasive bladder cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LP 20 (Primary)
  • Indications Bladder cancer
  • Focus Diagnostic use

Most Recent Events

  • 21 Aug 2024 According to a Lipella Pharmaceuticals media release, company will highlight clinical data on LP-20 at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024.
  • 10 Apr 2023 New trial record
  • 05 Apr 2023 According to a Lipella Pharmaceuticals media release, first patient has been dosed in this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top